View Older Stories View More Recent Stories

Aug 26, 2020 10:00AM Citius Pharmaceuticals Announces Improved Design and Expansion of Intellectual Property for Mino-Wrap
Aug 13, 2020 09:45AM Citius Pharmaceuticals to Present at the MoneyShow Las Vegas Virtual Expo
Aug 10, 2020 03:18PM Citius Pharmaceuticals Announces Closing of $9.6 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
Aug 5, 2020 09:00PM Citius Pharmaceuticals Increases Previously Announced Bought Deal Offering to $8.4 Million
Aug 5, 2020 05:33PM Citius Pharmaceuticals (CTXR) Announces $6 Million Bought Deal Offering of Common Stock
Aug 5, 2020 05:32PM Citius Pharmaceuticals Announces $6.0 Million Bought Deal Offering
Aug 4, 2020 08:18AM Citius Pharmaceuticals (CTXR) Submits Mino-Wrap Briefing Package to FDA for Pre-IND Consult
Aug 4, 2020 08:17AM Citius Submits Mino-Wrap Briefing Package to FDA for Pre-IND Consult
Jul 22, 2020 10:30AM Citius Pharmaceuticals Forms Scientific Advisory Board for the Planned Development of its Proprietary Treatment for Acute Respiratory Disease Associated with COVID-19
Jul 20, 2020 02:00PM Citius Pharmaceuticals to Present at the MoneyShow Accredited Investor Virtual Event
Jul 14, 2020 08:47AM Citius Pharmaceuticals Brings on Myron S. Czuczman, M.D. as Chief Medical Officer (CMO) and Executive Vice President
Jul 13, 2020 08:16AM Citius Pharmaceuticals (CTXR) Regains Compliance with Nasdaq Listing Requirements
Jul 13, 2020 08:15AM Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
Jun 29, 2020 09:07AM Citius CEO Myron Holubiak to Appear on TD Ameritrade Network's The Watch List with Nicole Petallides
Jun 26, 2020 09:06AM Citius Pharmaceuticals (CTXR) Receives FDA Response on Pre-IND Application for its iMSCs to Treat ARDS in Patients with COVID-19
Jun 26, 2020 09:00AM Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVI
Jun 22, 2020 01:17PM Citius Pharmaceuticals to Deliver Virtual Presentation at the Life Sciences Investor Forum
Jun 2, 2020 09:31AM Citius Pharmaceuticals (CTXR) Receives Positive FDA Feedback on Its Submitted Plan to Study Catheter Compatibility for Mino-Lok Therapy
Jun 2, 2020 09:30AM Citius Receives Positive FDA Feedback on Its Submitted Plan to Study Catheter Compatibility for Mino-Lok® Therapy
May 26, 2020 08:15AM Citius Announces Expanded Access Program for Investigational Phase 3 Mino-Lok®
May 18, 2020 02:30PM Citius Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
May 14, 2020 09:03AM Citius Pharmaceuticals (CTXR) Prices 7.058M Share Registered Direct Offering at $1.0625/Sh
May 14, 2020 09:00AM Citius Announces $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
May 13, 2020 08:15AM Citius Announces Data on NoveCite Mesenchymal Stem Cells (NC-MSCs) to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 12, 2020 08:00AM Citius Pharmaceuticals Issues May 2020 Shareholder Letter
Apr 27, 2020 09:33AM Citius Pharmaceuticals (CTXR) Reports Pre-IND Submission to FDA Under Coronavirus Treatment Acceleration Program for Novel Stem Cell Therapy for ARDS in COVID-19
Apr 27, 2020 09:30AM Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) in COVID-19
Apr 1, 2020 08:07AM Citius Pharmaceuticals (CTXR) Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for ARDS Associated with COVID-19
Apr 1, 2020 08:07AM Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19
Mar 26, 2020 09:06AM Citius Pharmaceuticals Announces Publication in Antimicrobial Agents and Chemotherapy Journal of Positive Preclinical Results for Mino-Lok® in Rapidly Eradicating Candida Auris
Mar 18, 2020 09:46AM Citius Pharmaceuticals to Deliver Virtual Presentation at the Spring Investor Summit
Mar 3, 2020 04:45PM Citius Pharmaceuticals, Inc. to Present at the Spring Investor Summit on March 25th-26th in New York City
Feb 26, 2020 08:00AM Citius Pharmaceuticals to Present at the 2020 LD Micro Virtual Conference
Feb 10, 2020 08:28AM Citius Pharmaceuticals to Present at Noble Capital Markets' 16th Annual Investor Conference
Feb 4, 2020 08:00AM Citius Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial
Feb 3, 2020 08:03AM Citius Pharmaceuticals (CTXR) Regains Compliance with Nasdaq Listing Requirements
Feb 3, 2020 08:00AM Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
Jan 24, 2020 07:23AM Citius Pharmaceuticals (CTXR) PT Raised to $4 at H.C. Wainwright
Dec 19, 2019 08:27AM Citius Pharmaceuticals (CTXR) to Resume Trading at 8:30 am
Dec 19, 2019 08:27AM Citius Pharmaceuticals (CTXR) Announces Positive Outcome of Interim Futility Analysis for its Phase 3 Mino-Lok Pivotal Trial
Dec 19, 2019 08:00AM Citius Announces Positive Outcome of Interim Futility Analysis for its Phase 3 Mino-Lok® Pivotal Trial
Dec 19, 2019 07:55AM Citius Pharmaceuticals (CTXR) Halted, News Pending
Dec 4, 2019 08:00AM Citius Pharmaceuticals to Present at the 12th Annual LD Micro Main Event
Nov 8, 2019 08:00AM Citius Pharmaceuticals Issues Corporate Update
Oct 24, 2019 08:00AM Citius Pharmaceuticals to Present at the 5th Annual Dawson James Small Cap Growth Conference
Oct 15, 2019 08:00AM Citius Pharmaceuticals to Present at the MicroCap Rodeo
Oct 7, 2019 08:30AM Citius Reaches First Interim Analysis Milestone for Mino-Lok® Pivotal Trial
Oct 3, 2019 07:00AM Citius Provides Update on Activities From IDWeek 2019
Sep 27, 2019 11:28AM Citius Announces Closing of $7.0 Million Underwritten Offering Priced At-the-Market
Sep 25, 2019 07:03AM Citius Pharmaceuticals (CTXR) Prices $7 Million Underwritten Offering Priced At-the-Market of Common Stock, Warrants
View More Recent Stories View Older Stories